Neuraxis, INC
No enriched coverage for $NRXS in the last 7 days.
No SEC Form 4 filings for $NRXS in the last 30 days.
See all $NRXS insider activity →DataMEDS AI (MEDS) rose 295.53% after acquiring Helomics for $1.5M, expanding into precision oncology. Tempest Therapeutics (TPST) gained 58.86% with a CAR-T licensing deal. NeurAxis (NRXS) increased 22.63% on expanded insurance coverage for its PENFS therapy. MAIA Biotechnology (MAIA) rose 5.22% after dosing the first U.S. patient in its THIO-101 trial.
NeurAxis (NRXS) shares rose 25% to $7.15 after announcing new medical coverage from a major insurer for its Percutaneous Electrical Nerve Field Stimulation, affecting 18 million members. The stock opened at $6.14 and peaked at $7.30.
NeurAxis (NRXS) announced that a major national insurer expanded coverage for its PENFS therapy, adding 18 million members, bringing total coverage to 120 million. The company's IB-Stim device is FDA-cleared for pediatric abdominal pain. CEO Brian Carrico highlighted growth acceleration and plans to pursue additional insurers. NRXS stock is up 21.77% to $6.94.
Recent NRXS coverage spans earnings, corporate actions and market movers.
Broader payer coverage increases addressable market and revenue visibility.
The coverage deal expands market access and could boost revenue, supporting further upside.
Coverage expansion likely boosts revenue and margins, supporting further upside.
Coverage approval expands market access and could drive revenue growth.
Strong margin and pricing indicate growth trajectory for the neuromodulation business.
AlphAI scores every news story that mentions NRXS with an AI model for sentiment and relevance, and aggregates insider trades from Neuraxis, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
DataMEDS AI (MEDS) rose 295.53% after acquiring Helomics for $1.5M, expanding into precision oncology. Tempest Therapeutics (TPST) gained 58.86% with a CAR-T licensing deal. NeurAxis (NRXS) increased 22.63% on expanded insurance coverage for its PENFS therapy. MAIA Biotechnology (MAIA) rose 5.22% after dosing the first U.S. patient in its THIO-101 trial.
3 min readNeurAxis (NRXS) shares rose 25% to $7.15 after announcing new medical coverage from a major insurer for its Percutaneous Electrical Nerve Field Stimulation, affecting 18 million members. The stock opened at $6.14 and peaked at $7.30.
1 min readNeurAxis (NRXS) announced that a major national insurer expanded coverage for its PENFS therapy, adding 18 million members, bringing total coverage to 120 million. The company's IB-Stim device is FDA-cleared for pediatric abdominal pain. CEO Brian Carrico highlighted growth acceleration and plans to pursue additional insurers. NRXS stock is up 21.77% to $6.94.
2 min readNeurAxis (NRXS) announced a major national health insurer will cover its IB-Stim device for treating abdominal pain in patients aged 8+. The coverage applies to 18M members across multiple states. The FDA-cleared device is a non-invasive neuromodulation technology. NeurAxis aims to secure coverage from more insurers and is conducting additional clinical trials. The company did not disclose the insurer's name or provide financial projections.
2 min readEastman Kodak (KODK) reported 18% YOY revenue growth to $311M, with print and advanced materials segments up 10% and 40% respectively. Gross margin improved 700 bps to 26%, and operational EBITDA grew to $36M. The company is exploring new markets like EV batteries and pharma reagents. NeurAxis (NRXS) also shows potential with high gross margins and product traction.
3 min readNeuraxis, INC (NRXS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (e) Compensatory Arrangements of Certain Officers Stock Option Exchange As previously disclosed, on June 10, 2026, the stock
1 min readNeurAxis (NRXS) shares fell after Q2 2026 results for the quarter ended June 30. Revenue rose to $1.9M, up 115.7% year over year, and loss per share narrowed to $0.19. Net loss and operating loss widened to $2.1M each. Gross margin increased to 85.9% from 83.6% as average selling price rose 28% to $992. Cash was $8.3M.
6 min readNeurAxis (NRXS) reported Q2 2026 revenue of $1.928 million, up 116% year over year, driven by increased payer and reimbursement coverage, with IB-Stim ASP rising to $992 per device (+28%). Gross margin was 85.9%. Operating loss was $2.1 million and net loss $2.1 million. Cash on hand was $8.3 million as of June 30, 2026.
6 min readNeurAxis (NYSE American: NRXS) reported Q2 2026 revenue of $1.9M, up 116% year over year, citing PENFS Category I CPT code coverage effective Jan. 1, 2026. Gross margin rose to 85.9%. Cash was $8.3M at June 30, 2026. The company also cited VA FSS contract and FDA clearance for functional dyspepsia abdominal pain.
4 min readNeuraxis, INC (NRXS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan (As Amended As of June 11, 2026) Table of Contents Page ARTICLE I PURPOSE 1 ARTICLE II DEFINITIONS 1 ARTICLE III EFFECTIVE DATE OF PLAN 6 ARTICLE IV ADMINISTRATION 6 Section 4.1 Ad
2 min read
